Malign mezotelyomada bazı klinikopatolojik parametrelerin ve gen protein ekspresyonlarının prognostik analizi

Giriş: Mezotelyoma, seröz yüzeylerden kaynaklanan agresif seyirli bir tümördür. Bu çalışmanın birincil sonlanım noktası, progresyonsuz sağkalım (PS) ve genel sağkalım (GS) ile plevral ve peritoneal mezotelyoma olgularındaki tümör dokusunda c-Met, EGFR, PTEN, PDGFR-alfa, PI3K/AKT ve mTOR ekspresyon düzeylerinin ilişkisini incelemekti. Materyal ve Metod: Çalışmaya 2005-2016 yılları arasında mezotelyoma tanısı konan 53 hasta dahil edildi. Olgular plevral ve peritoneal olmak üzere iki gruba ayrıldı. GS ve PS üzerindeki etkiler c-Met, EGFR, PTEN, PDGFR-alfa, PI3K/AKT ve mTOR ekspresyon düzeyleri ile klinikopatolojik parametreler ve verilen tedaviler açısından incelendi. Elde edilen verilerin istatistiksel analizinde IBM SPSS vn 20.0 yazılımı kullanıldı. Bulgular: Çalışmaya dahil edilen 53 hastadan 39 (%73.6)’una plevral mezotelyoma, 14 (%26.4)’üne peritoneal mezotelyoma tanısı kondu. c-Met ve mTOR ekspresyonuna göre; yüksek eksprese olan (2+, 3+) peritoneal olguların GS ve PS oranlarının, düşük eksprese (0, 1+) olan peritoneal olgulardan anlamlı olarak daha iyi olduğu görüldü (p< 0.05). PDGFR ekspresyonuna göre; düşük eksprese olan (0, 1+) plevral olguların GS ve PS oranlarının, yüksek eksprese olan (2+, 3+) plevral olgulardan anlamlı olarak daha iyi olduğu görüldü (p< 0.05). Sonuç: Mezotelyoma olgularının biyopsi ve operasyon materyallerinde c-Met, PDGFR-alfa ve mTOR ekspresyonunun incelenmesi prognozun belirlenmesinde önemli olabilir.

The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma

Introduction: Mesothelioma is an aggressive tumour that originates in seroussurfaces. The primary end point of this study was to invastigate the relationshipof progression free survival (PFS) and overall survival (OS) with the c-Met,EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expression levels in thetumour tissue of pleural and peritoneal mesothelioma cases.Materials and Methods: The study included 53 patients diagnosed withmesothelioma between 2005 and 2016. The cases were separated into 2groups as pleural and peritoneal. The effects on OS and PFS were examinedof the c-Met, EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expressionlevels and also clinicopathological parameters and the treatments given. In thestatistical analysis of the data obtained, IBM SPSS vn 20.0 software was used.Results: Of the 53 patients included in the study, 39 (73.6%) were diagnosedwith pleural mesothelioma and 14 (26.4%) with peritoneal mesothelioma.According to the c-Met and mTOR expression, OS and PFS of the peritonealcases with high expression (2+, 3+) was seen to be significantly better thanthat of the peritoneal cases with low expression (0, 1+) (p< 0.05). Accordingto the PDGFR expression, OS and PFS of the pleural cases with low expression(0, 1+) was seen to be significantly better than that of the pleural cases withhigh expression (2+, 3+) (p< 0.05).Conclusion: The examination of c-MET, PDGFR-alpha and m-TOR expressionin the in the tumor tissue of mesothelioma cases may be important indetermining prognosis.

PDF

___

1. Tischoff I, Tannapfel A. Mesothelioma. Pathologe 2017;38:547-60.
2. Lemen RA. Mesothelioma from asbestos exposures: epidemiologic patterns and impact in the United States. J Toxicol Environ Health B Crit Rev 2016;19:250-65.
3. Mensi C, Mendola M, Dallari B, Sokooti M, Tabibi R, Riboldi L, et al. Differences between peritoneal and pleural mesothelioma in Lombardy, Italy. Cancer Epidemiol 2017;51:68-73.
4. Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, et al. c-Met expression and MET amplification in malignant pleural mesothelioma. Ann Diagn Pathol 2016;23:1-7.
5. Liang Y, Zheng G, Yin W, Song H, Li C, Tian L, et al. Significance of EGFR and PTEN expression and PLR and NLR for predicting the prognosis of epithelioid malignant peritoneal mesothelioma. Gastroenterol Res Pract 2019;2019:7103915.
6. Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 2017;17:475-88.
7. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008;33:502-6.
8. Metheny-Barlow LJ, Flynn B, van Gijssel HE, Marrogi A, Gerwin BI. Paradoxical effects of plateletderived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol 2001;24:694-702.
9. Ramos-Nino ME, Vianale G, Sabo-Attwood T, Mutti L, Porta C, Heintz N, et al. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther 2005;4:835-42.
10. Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, et al. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol 2011;179:1483-93.
11. Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, et al. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Lung Cancer 2016;96:1-6.
12. Levallet G, Vaisse-Lesteven M, Le Stang N, Ilg AG, Brochard P, Astoul P, et al. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignantmesothelioma: a series of 157 cases from the MESOPATH Group. J Thorac Oncol 2012;7:599-606.
13. Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012;7:340-7.
14. Opitz I, Soltermann A, Abaecherli M. PTEN expression is a strong predictor of survival in mesothelioma patients. European Journal of Cardio-thoracic Surgery 2008;33:501- 5.
15. Agarwal V, Campbell A, Beaumont KL. PTEN protein expression in malignant pleural mesothelioma. Tumor Biol 2013;34:847-51.
16. Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, et al. Activation of the PI3K-AKTpathway in human malignant mesothelioma cells. Mol Med Rep 2009;2:181-8.
17. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, et al. Human and mouse mesotheliomas exhibit elevated akt/pkb activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005;24:6080-9.
18. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase 2 study of erlotinib in patients with malignant pleural mesothelioma: a southwest oncology group study. J Clin Oncol 2007;25:2406-13.
19. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev 2006;5:671-8.
20. Kucukoner M, Isikdoğan A. mTOR signaling pathway and mTOR inhibitors in the treatment of cancer. Dicle Medical Journal 2013;40:156-60.
21. Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, Abdel-Hamid A, et al. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 2010;70:43-50.
22. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11:23004.
23. Zimmerman RL, Fogt F. Evaluation of the c-Met immunostain to detect malignant cells in body cavity effusions. Oncol Rep 2001;8:1347-50.
24. Appiah-Kubi K, Wang Y, Qian H, Wu M, Yao X, Wu Y, et al. Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers. Tumour Biol 2016;37:10053-66.
25. Soeberg MJ, Creighton N, Currow DC, Young JM, van Zandwijk N. Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009. Aust N Z J Public Health 2016;40:255-62.
26. Alexander HR Jr, Li CY, Kennedy TJ. Current management and future opportunities for peritoneal metastases: peritoneal mesothelioma. Ann Surg Oncol 2018;25:2159-64.